On January 8, 2010, the U.S. Food and Drug Administration approved tocilizumab (to be marketed under the trade name of Actemra) for the treatment of patients with moderate to severe rheumatoid arthritis who have had inadequate clinical responses to treatment with TNF inhibitors. Tocilizumab is a humanized monoclonal antibody directed against the receptor for IL-6, a cytokine increased in the blood and joints of RA patients and a contributor to many of the signs and symptoms of RA. The drug is administered as a monthly intravenous infusion dosed on weight.
A Small Favor
More than 15 years ago the Arthritis Center launched this website with the mission to bring current and accurate disease education to health care professionals and patients alike. Content on our site is generated directly by our team members. Unlike many health education websites we do not accept advertising, paid guests posts or charge for access to our site.
That’s where you come in. Your support will allow us to continue to deliver this valuable information to over 1 million visitors each year.Contribute TodayMore Ways to Give